Investigating how a virus responsible for serious infections in children is assembled
Official title: Tegument Envelope Protein Interactions in CMV Envelopment
Funded at University of Alabama at Birmingham · NIH-10975028 · Data updated 2026-11-12
This study is looking at how the human cytomegalovirus (HCMV) works, especially in people with weakened immune systems and babies, to find better ways to create vaccines and medicines that can help fight this virus and keep everyone healthier.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project start | November 8, 2022 |
| Project end | October 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $466,698 |
| NIH project number | 5R01AI173778-03 |
| Project ID | NIH-10975028 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include infants and children under 11 years old who are at risk of HCMV infection or have been diagnosed with related health issues.
✕Less likely to help
Patients who are not affected by HCMV or are over the age of 11 may not receive any benefit from this research.
What this research studies
This research focuses on understanding the human cytomegalovirus (HCMV), which can cause severe health issues in immunocompromised individuals and lead to developmental problems in infants. The team will explore how the virus is assembled within cells by studying specific protein interactions that are crucial for its replication. By using modified viruses with targeted mutations, they aim to uncover new strategies for developing vaccines and antiviral drugs that could effectively combat HCMV. This research could pave the way for safer and more effective treatments for those affected by this virus.
Why it matters
Potential benefit: If successful, this research could lead to the development of new antiviral therapies and vaccines for HCMV, significantly improving health outcomes for affected patients.
How similar studies have gone: Previous research has shown promise in targeting viral assembly mechanisms, suggesting that this approach could yield significant advancements in antiviral therapy.
Where this research is happening
-
University of Alabama at Birmingham
Birmingham, United States Active
Researchers
- Principal investigator: Britt, William Jarvis — University of Alabama at Birmingham
- Study coordinator: Britt, William Jarvis
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.